Literature DB >> 28972593

Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.

G Kerdivel1,2,3,4,5, V Chesnais1,2,3,4,6, E Becht4,7,8, A Toma9, N Cagnard10, F Dumont1,2,3,4,11, A Rousseau12, P Fenaux13, S Chevret14, N Chapuis1,2,3,4,6,12, V Boeva1,2,3,4,5, W H Fridman4,7, M Fontenay1,2,3,4,6,12, O Kosmider1,2,3,4,6,12.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28972593     DOI： 10.1038/leu.2017.305

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  17 in total

1.  Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.

Authors:  Valeria Santini; Antonio Almeida; Aristoteles Giagounidis; Stefanie Gröpper; Anna Jonasova; Norbert Vey; Ghulam J Mufti; Rena Buckstein; Moshe Mittelman; Uwe Platzbecker; Ofer Shpilberg; Ron Ram; Consuelo Del Cañizo; Norbert Gattermann; Keiya Ozawa; Alberto Risueño; Kyle J MacBeth; Jianhua Zhong; Francis Séguy; Albert Hoenekopp; C L Beach; Pierre Fenaux
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

Review 2.  Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.

Authors:  Shikhar Aggarwal; Arjan A van de Loosdrecht; Canan Alhan; Gert J Ossenkoppele; Theresia M Westers; Hetty J Bontkes
Journal:  Br J Haematol       Date:  2011-04-13       Impact factor: 6.998

3.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.

Authors:  Elaine M Sloand; Lori Mainwaring; Monika Fuhrer; Shakti Ramkissoon; Antonio M Risitano; Keyvan Keyvanafar; Jun Lu; Atanu Basu; A John Barrett; Neal S Young
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

5.  Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome.

Authors:  Alexander Sternberg; Sally Killick; Tim Littlewood; Chris Hatton; Andy Peniket; Thomas Seidl; Shamit Soneji; Joanne Leach; David Bowen; Claire Chapman; Graham Standen; Edwin Massey; Lisa Robinson; Bipin Vadher; Richard Kaczmarski; Riaz Janmohammed; Kim Clipsham; Andrew Carr; Paresh Vyas
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

6.  Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Authors:  A Toma; O Kosmider; S Chevret; J Delaunay; A Stamatoullas; C Rose; O Beyne-Rauzy; A Banos; A Guerci-Bresler; S Wickenhauser; D Caillot; K Laribi; B De Renzis; D Bordessoule; C Gardin; B Slama; L Sanhes; B Gruson; P Cony-Makhoul; B Chouffi; C Salanoubat; R Benramdane; L Legros; E Wattel; G Tertian; K Bouabdallah; F Guilhot; A L Taksin; S Cheze; K Maloum; S Nimuboma; C Soussain; F Isnard; E Gyan; R Petit; J Lejeune; V Sardnal; A Renneville; C Preudhomme; M Fontenay; P Fenaux; F Dreyfus
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

7.  Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.

Authors:  Jan Krönke; Emma C Fink; Paul W Hollenbach; Kyle J MacBeth; Slater N Hurst; Namrata D Udeshi; Philip P Chamberlain; D R Mani; Hon Wah Man; Anita K Gandhi; Tanya Svinkina; Rebekka K Schneider; Marie McConkey; Marcus Järås; Elizabeth Griffiths; Meir Wetzler; Lars Bullinger; Brian E Cathers; Steven A Carr; Rajesh Chopra; Benjamin L Ebert
Journal:  Nature       Date:  2015-07-01       Impact factor: 49.962

8.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.

Authors:  Etienne Becht; Nicolas A Giraldo; Laetitia Lacroix; Bénédicte Buttard; Nabila Elarouci; Florent Petitprez; Janick Selves; Pierre Laurent-Puig; Catherine Sautès-Fridman; Wolf H Fridman; Aurélien de Reyniès
Journal:  Genome Biol       Date:  2016-10-20       Impact factor: 13.583

9.  Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.

Authors:  Ashley A Basiorka; Kathy L McGraw; Leentje De Ceuninck; Lori N Griner; Ling Zhang; Justine A Clark; Gisela Caceres; Lubomir Sokol; Rami S Komrokji; Gary W Reuther; Sheng Wei; Jan Tavernier; Alan F List
Journal:  Cancer Res       Date:  2016-04-06       Impact factor: 12.701

10.  An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.

Authors:  Benjamin L Ebert; Naomi Galili; Pablo Tamayo; Jocelyn Bosco; Raymond Mak; Jennifer Pretz; Shyam Tanguturi; Christine Ladd-Acosta; Richard Stone; Todd R Golub; Azra Raza
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069
View more
  2 in total

1.  Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.

Authors:  Thorben Mährle; Nuray Akyüz; Pim Fuchs; Nicola Bonzanni; Donjete Simnica; Ulrich Germing; Anne Marie Asemissen; Johann Christoph Jann; Florian Nolte; Wolf-Karsten Hofmann; Daniel Nowak; Mascha Binder
Journal:  Haematologica       Date:  2019-01-17       Impact factor: 9.941

2.  Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.

Authors:  Leylah M Drusbosky; Christopher R Cogle
Journal:  Int J Mol Sci       Date:  2020-05-08       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.